Intravitreal Bevacizumab in treatment of chronic central serous chorioretinopathy: the efficacy according to indocyanine green angiography findings

Abstract

AbstractPurpose To evaluate the efficacy of bebacizumab according to baseline indocyanine green angiography (ICGA) findings for treatment of chronic central serous chorioretinopathy (CSC).Methods Twenty‐two eyes of 22 patients with chronic CSC and symptoms for at least 3 months were treated with intravitreal injections of 1.25 mg (0.05 ml) bevacizumab. The mean follow‐up was 12.5 months. The degrees of hyperfluorescence of ICGA included intense, weak , or no hyperfluorescence . Main outcomes measures were the resolution of the subretinal fluid and visual acuity.Results On the basis of ICGA, intense hyperfluorescence was found in 5 eyes (23%), diffusely weak hyperfluorescence in 6 eyes (27%), focally weak hyperfluorescence in 7 eyes (32%) and no hyperfluorescence in 4 eyes (18 %). The complete resolution rate of the subretinal fluid was higher in eyes with focally weak and no hyperfluorescence (4 eyes (57%) and 2 eyes (50%)) than in eyes with intense and diffuse weak hyperfluorescence (1 eye (20%) and 2 eyes(33%)). Visual acuty was increased in eyes with complete (n=9, 0.20) and partial (n=5, 0.11) resolution of the subretinal fluid. However, in eyes without response, visual acuity was rather decreased (n=8, ‐0.11).Conclusion The efficacy of bebacizumab in eyes with chronic CSC was heterogeneous according to baseline ICGA findings and seemed to be higher in eyes with lower choroidal permeability on ICGA.